11:23 AM EDT, 04/17/2024 (MT Newswires) -- Celldex Therapeutics ( CLDX ) said Wednesday that enrollment of patients has been completed in its phase 2 clinical study of barzolvolimab for the treatment of cold urticaria and symptomatic dermographism, the two most common types of chronic inducible urticarial.

Cold urticaria symptoms include itching, burning wheals and angioedema when skin is exposed to temperatures below skin temperature, while symptomatic dermographism symptoms include the development of wheals and a flare reaction in response to stroking, scratching or rubbing of the skin.

The company said the study will assess the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients who remain symptomatic despite antihistamine therapy, to decide the optimal dosing strategy.

Celldex shares were up 4.3% in recent trading.